| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors (NCT05176483) | Exelixis | 2021-12-14 |
| A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors (NCT06630429) | Ohio State University Comprehensive Cancer Center | 2020-09-02 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis (NCT04187872) | University of Florida | 2020-01-10 |
| Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC (NCT04375150) | Pfizer | 2019-12-02 |
| Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (NCT03647163) | Vyriad, Inc. | 2019-04-09 |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) (NCT03634540) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2018-09-27 |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NCT03549000) | Novartis Pharmaceuticals | 2018-07-18 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies (NCT03538028) | Incyte Biosciences International Sàrl | 2018-06-18 |
| A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors (NCT03311334) | Sumitomo Pharma America, Inc. | 2017-12-14 |
| Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) (NCT03260894) | Incyte Corporation | 2017-12-07 |
| Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors (NCT02903914) | Incyte Corporation | 2016-09-14 |
| FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS (NCT03955393) | IRCCS San Raffaele | 2016-09-01 |
| A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma (NCT02837991) | Celldex Therapeutics | 2016-06-01 |
| Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors (NCT02646748) | Incyte Corporation | 2016-01-25 |
| CT-based Radiomics for Prediction of MIT Family Translocation Kidney Cancer: a Multicenter, Retrospective Clinical Study (NCT07181954) | First Affiliated Hospital of Fujian Medical University | 2016-01-15 |
| Computed Tomography Radiomics-Derived Nomogram for Predicting Early Renal Function Decline After Partial Nephrectomy in Renal Cell Carcinoma: A Multicenter Development/Validation Study (NCT07117786) | First Affiliated Hospital of Fujian Medical University | 2016-01-01 |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers (NCT02178722) | Incyte Corporation | 2014-07-17 |
| PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy (NCT01666353) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2012-04-16 |
| Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma (NCT00520533) | Ludwig Institute for Cancer Research | 2008-02-01 |
| Phase 2 Study in Patients With MiT Tumors (NCT00557609) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2007-10-01 |
| Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. (NCT00199888) | Ludwig Institute for Cancer Research | 2005-06-01 |